Exchange: NYSE·Updated 07:30 PM EST

ANRO News

News
all
press releases
Alto Neuroscience (NYSE:ANRO) Stock: Insider Jr. Michael Conick Hanley Sells 2,896 Shares
Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) COO Jr. Michael Conick Hanley sold 2,896 shares of the stock in a transaction that occurred on Wednesday, November 18th. The shares were sold at an average price of $26.48, for a total transaction of $76,686.08. Following the completion of the...
MarketBeat
Alto Neuroscience (NYSE:ANRO) Stock: Insider Jr. Michael Conick Hanley Sells 2,896 Shares
Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) COO Jr. Michael Conick Hanley sold 2,896 shares of the stock in a transaction that occurred on Wednesday, November 18th. The shares were sold at an average price of $26.48, for a total transaction of $76,686.08. Following the completion of the...
MarketBeat
More News
Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) COO Jr. Michael Conick Hanley sold 2,104 shares of the business's stock in a transaction dated Tuesday, November 17th. The stock was sold at an average price of $26.82, for a total value of $56,429.28. Following the transaction, the chief...
MarketBeat
Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) COO Jr. Michael Conick Hanley sold 70,000 shares of the stock in a transaction dated Monday, November 16th. The stock was sold at an average price of $27.68, for a total transaction of $1,937,600.00. Following the transaction, the chief...
MarketBeat
Alto Neuroscience (NYSE:ANRO) Shares Up 8.4% - Here's Why...
MarketBeat
Alto Neuroscience (NYSE:ANRO) Shares Gap Down - What's Next...
MarketBeat
Here is how UnitedHealth Group (UNH) and Alto Neuroscience, Inc. (ANRO) have performed compared to their sector so far this year.
Zacks
Alto Neuroscience, Inc. (ANRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
The mean of analysts' price targets for Alto Neuroscience, Inc. (ANRO) points to a 29.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended September 30, 2026, and highlighted recent progress across its...
Business Wire
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that on November 3, 2026, the Compensation and Management Development Committee of Altos Board of Directors...
Business Wire

Advertisement|Remove ads.